Biogen Opts To Retain Biosimilars Business

After Strategic Review, Firm Decides To ‘Optimize’ Its Interests In Biosimilars

Following a “comprehensive review” of its biosimilars business – including exploring options to sell the unit – Biogen has decided to retain it after all, and is instead planning to “optimize the business with an aim to maximize profitability.”

Gloved hands holding syringe and vial with Biogen label
Biogen is holding on to its biosimilars interests • Source: Shutterstock

After more than a year of deliberation over the future of its biosimilars business, Biogen has opted to retain the unit after all, pledging instead to “optimize the business with an aim to maximize profitability.”

More than a year ago, Biogen CEO Chris Viehbacher revealed that the firm had a “formal process underway to evaluate strategic options for our biosimilars business,” having previously hinted that “we are looking at whether we can

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

More from Business

Teva And Alvotech Celebrate Interchangeability For US Ustekinumab

 
• By 

The market for biosimilar rivals to Stelara continues to be hotly contested in the US, with partners Teva and Alvotech claiming a boost from an interchangeability designation at the same time as Biocon Biologics highlighted fresh market access agreements.

Amgen Biosimilars Continue Surge Ahead Of Imminent Denosumab Competition

 
• By 

Thanks to its efficient development pipeline, sales of Amgen’s biosimilars neared $750m for the first three months of the year, offering some comfort as the firm gears up for the loss of exclusivity for its denosumab franchise.

Adalvo And Gedeon Richter Join Forces On Semaglutide

 
• By 

Adalvo and Gedeon Richter have announced a global co-development deal for semaglutide for obesity. Adalvo CEO Anil Okay spoke to Generics Bulletin about the alliance as well as the broader competitive landscape for GLP-1s.